Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11352700 | 0.81 | NOTUM (0.37) | MAP3K14OPRM1OPRL1CYP11B1CYP11B2 | |
| SCHEMBL22102913 | 0.78 | OPRL1 (0.37) | MAP3K14OPRM1OPRL1CYP11B1CYP11B2 | |
| SCHEMBL29660414 | 0.78 | MAP3K14 (0.34) | MAP3K14OPRM1OPRL1CYP11B1CYP11B2 | |
| SCHEMBL22102579 | 0.78 | MAP3K14 (0.34) | MAP3K14OPRM1OPRL1CYP11B1CYP11B2 | |
| SCHEMBL15287132 | 0.78 | MAP3K14 (0.34) | MAP3K14OPRM1OPRL1CYP11B1CYP11B2 | |
| SCHEMBL22102575 | 0.78 | OPRM1 (0.34) | MAP3K14OPRM1OPRL1CYP11B1CYP11B2 | |
| SCHEMBL11110438 | 0.77 | HTR2C (0.45) | MAP3K14OPRM1OPRL1POLL | |
| SCHEMBL1508419 | 0.77 | HTR2C (0.45) | MAP3K14OPRM1OPRL1POLL | |
| SCHEMBL1508379 | 0.77 | HTR2C (0.45) | MAP3K14OPRM1OPRL1POLL | |
| SCHEMBL30748004 | 0.74 | NOTUM (0.41) | MAP3K14OPRM1OPRL1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020119592-A1 | NOVEL THREE-RING FUSED STRUCTURE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 信达生物制药(苏州)有限公司 | 2020-06-18 | — | — | WO | disclosed |